Pfizer meets forecasts with 2025 guidance

(Sharecast News) - Shares in pharmaceutical and biotech giant Pfizer were on the rise on Tuesday after the New York-based outfit delivered guidance for 2025 that met analysts' forecasts. The company pointed to annual revenues of $61bn to $64bn for next year, in line with guidance for 2024, despite an expected $1bn negative hit from changes to the US government's drug price controls. Current FactSet consensus is for a figure close to $63.2bn.

Diluted earnings per share are expected to total $2.80 to $3.00 in 2025, which it said reflects expected operational growth or 10-18% year-on-year based on the midpoint of the guidance of $2.75 to $2.95 for 2024. The market forecast for next year is $2.86.

"Pfizer is in a strong position to continue making a positive impact for patients and delivering on our financial commitments in 2025," said chair and chief executive Albert Bourla. "We also expect to continue improving our operating margins with focused financial discipline."

Bourla said the company has met its goal of $4bn in net operating expensive savings through 2024 from its "cost realignment programme", with an additional $500m expected to be saved in 2025.

The stock was up 3.8% at $26.23 by 1052 ET.